“We were scared patients would bleed out”
Chapter 4. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. This third installment details how the first doses given to patients were little more than water, as there was a real fear of damage to the body’s cells.
BY LONNI LYNGE
When chief physician Torben Plesner takes a trip from Vejle to Copenhagen on April 12th 2007, he has packed a great deal of skepticism. In a Powerpoint presentation he has listed page after page of significant risks that might be associated with the candidate drug HuMax-CD38, also known as daratumumab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Popping the cork
For abonnenter
”It’s a slam dunk”
For abonnenter
Management wants to kill off dara – more than once
For abonnenter
